The formulation is based on amifostine as the main component and employs patented composite micelles, triggered controlled-release technology, and a special formulation to extend its half-life. It is designed as a preventive medication for entities concerned with radiation hazards, such as nuclear power plants, military chemical and nuclear units, and hospitals conducting proton radiation therapy. According to the aforementioned clinical prevention methods, the drug carrier is designed to use functional excipients to transport the medication, forming 20-50 nanometer-sized micelles. This approach extends the distribution time within the body and protects amifostine from losing its activity. It achieves prolonged antioxidant effects and safeguards radiation-sensitive organs like the hematopoietic system.
OBM-A01 is applied to acute radiation injuries, including nuclear radiation and solar radiation exposure in space. By employing carrier technology to encapsulate the drug amifostine, it effectively extends the protective effect during radiation damage and achieves preventive outcomes.
Radiation injury is classified under rare drugs and categorized as emergency-use medication. Its development process can be accelerated to obtain drug approval based on animal efficacy principles combined with Phase I clinical trial safety results. OBM-A01 obtained permission for Phase I clinical safety trials in 2015.
The development of OBM-A01 for other indications as an ultrasound contrast agent has benefited from prior experience, allowing the prediction of the maximum drug dosage and other safety evaluations. In animal studies, it has already demonstrated advantageous data compared to competing products on the market.
